From £6.99 per month
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares


Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Results: EKF

Search articles by EPIC code

EKF Diagnostics – argues remains positive of capacity expansion “significant benefit”... but not sufficiently for the CEO to remain in situ?!

EKF Diagnostics (EKF) has issued a “trading update” – it stating “reflecting strong growth in the core established business… also gives a progress update on the expansion of the Life Sciences enzyme fermentation business and on the transition of Contract Manufacturing & Laboratory Testing into non-COVID revenues”. So what of a share price response to currently 32.6p, approaching 17% lower?
Page 1 of 2 (14 articles)
Subscribe to our newsletter

Daily digest of our latest stories.

Search ShareProphets

Complete Coverage

Recent Comments